About Atisa Lifesciences
Atisa Lifesciences is a Healthcare company based in Hyderabad (India) founded in 2018. It manufactures and supplies affordable medicines in oncology, nephrology, and hepatology sectors. It operates on a B2B and Manufacturing and Distribution model. Its Indian entity Atisa Life Sciences Private Limited reported revenue of ₹13.5 Lakh. Atisa Lifesciences offers products and services including Futran, Tidar, Peglip, Zyterone, and Lenodo. Its focus areas include Pharmaceuticals, Oncology, Solid Tumors and Nephrology.
Company details
Atisa Lifesciences is a specialty pharmaceutical company based in India, emphasizing high-quality medicine production adhering to GMP guidelines. It focuses on therapeutic areas like oncology, nephrology, and hepatology, developing innovative drugs through research and collaboration. The company aims to improve patient survival and quality of life by providing affordable treatments globally, with manufacturing processes ensuring regulatory compliance and stringent standards.
- Headquarters Hyderabad, India
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website atisalifesciences.com
- Legal Name Atisa Life Sciences Private Limited
- Date of Incorporation 21 Dec, 2010
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹13.5 Lakh
FY 2025 · -20% YoY
- Net Loss-₹54.1 Lakh
FY 2025 · -401% margin
- EBITDA-₹41.2 Lakh
FY 2025 · -305% margin
Associated legal entities of Atisa Lifesciences
Atisa Lifesciences operates through Atisa Life Sciences Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Atisa Life Sciences Private Limited CIN U24233TG2010PTC071785 | Active | 21 Dec 2010 | Hyderabad, Telangana | ₹0.1 Cr | 3 | View details |
Products & Services of Atisa Lifesciences
Atisa Lifesciences offers a comprehensive portfolio of products and services, including Futran, Tidar, Peglip, Zyterone, and Lenodo.
Fulvestrant injection for treating breast cancer patients
Temozolomide injection used in brain tumor therapy
Pegylated liposomal doxorubicin for cancer treatment
Abiraterone acetate tablets for prostate cancer care
Lenalidomide capsules for multiple myeloma management
Board of directors of Atisa Life Sciences Private Limited (Atisa Lifesciences)
Atisa Life Sciences Private Limited is the primary company behind Atisa Lifesciences. The board of Atisa Life Sciences Private Limited currently have 3 directors; the longest-serving is Somasundaram Shanmugam, appointed in 2010. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Somasundaram Shanmugam DIN 02425917 | Director | 21 Dec 2010 | 15 yrs 10 mo | Atisa Life Sciences Private Limited |
| Udayalakshmi Suresh DIN 11196301 | Director | 31 Jul 2025 | 1 yr 3 mo | Atisa Life Sciences Private Limited |
| Sandhya Nandiraju DIN 07697975 | Director | 31 Jul 2025 | 1 yr 3 mo | Atisa Life Sciences Private Limited |
Financials of Atisa Lifesciences
Figures of Atisa Life Sciences Private Limited, the primary company behind Atisa Lifesciences, for FY 2025. Revenue was ₹13.5 Lakh (-20% year on year). Net loss was -₹54.1 Lakh (-401% margin). EBITDA was -₹41.2 Lakh (-305% margin). Revenue has grown at a compounded annual rate of -36% over three years and -26% over five years.
- ₹13.5 LakhRevenue · FY 2025 · -20% YoY
- -₹54.1 LakhNet loss · -401% margin
- -₹41.2 LakhEBITDA · -305% margin
- ₹4.72 CrPaid-up capital
- -36%Revenue CAGR, 3 years
- -26%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Atisa Life Sciences Private Limited are on its company page.
Detailed financial statements for Atisa Lifesciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Atisa Lifesciences
Atisa Lifesciences was founded in 2018.
Atisa Lifesciences is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
The primary company behind Atisa Lifesciences, Atisa Life Sciences Private Limited, reported revenue of ₹13.5 Lakh for FY 2025, down 20% year on year.
Atisa Lifesciences is a specialty pharmaceutical company based in India, emphasizing high-quality medicine production adhering to GMP guidelines. It focuses on therapeutic areas like oncology, nephrology, and hepatology, developing innovative drugs through research and collaboration. The company aims to improve patient survival and quality of life by providing affordable treatments globally, with manufacturing processes ensuring regulatory compliance and stringent standards.
Atisa Lifesciences offers Futran, Tidar, Peglip, Zyterone, and Lenodo.
Atisa Lifesciences operates through Atisa Life Sciences Private Limited.
The legal entities of Atisa Lifesciences currently have 3 directors, including Somasundaram Shanmugam, Udayalakshmi Suresh, Sandhya Nandiraju.